We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Neurelis

News List

Neurelis Completes Pre-IND Meeting with FDA for Acute Agitation Treatment americanpharmaceuticalreview
December 09, 2020
Neurelis has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4. The FDA provided direction for the clinical development pathway for the investigational treatment.
FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment drugs
January 14, 2020
Neurelis, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizure